AU2010298166B2 - Pyrido[4,3-b]indoles and methods of use - Google Patents

Info

Publication number

AU2010298166B2

AU2010298166B2 AU2010298166A AU2010298166A AU2010298166B2 AU 2010298166 B2 AU2010298166 B2 AU 2010298166B2 AU 2010298166 A AU2010298166 A AU 2010298166A AU 2010298166 A AU2010298166 A AU 2010298166A AU 2010298166 B2 AU2010298166 B2 AU 2010298166B2

Authority

AU

Australia

Prior art keywords

substituted

moiety

unsubstituted

variation

alkyl

Prior art date

2009-09-23

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 77
• RDMFHRSPDKWERA-UHFFFAOYSA-N 5H-Pyrido[4,3-b]indole Chemical class C1=NC=C2C3=CC=CC=C3NC2=C1 RDMFHRSPDKWERA-UHFFFAOYSA-N 0.000 title abstract description 4
• 150000001875 compounds Chemical class 0.000 claims abstract description 503
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 126
• 208000010877 cognitive disease Diseases 0.000 claims abstract description 59
• 208000028017 Psychotic disease Diseases 0.000 claims abstract description 54
• 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 41
• 230000001537 neural effect Effects 0.000 claims abstract description 39
• 230000001404 mediated effect Effects 0.000 claims abstract description 38
• 238000011282 treatment Methods 0.000 claims abstract description 31
• 150000003839 salts Chemical class 0.000 claims description 66
• 239000003814 drug Substances 0.000 claims description 16
• 239000003937 drug carrier Substances 0.000 claims description 8
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 102000000543 Histamine Receptors Human genes 0.000 abstract description 34
• 108010002059 Histamine Receptors Proteins 0.000 abstract description 34
• 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
• 230000001225 therapeutic effect Effects 0.000 abstract description 7
• 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 342
• 125000000217 alkyl group Chemical group 0.000 description 141
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 126
• -1 perhaloalkyl Chemical group 0.000 description 112
• 230000000694 effects Effects 0.000 description 104
• 125000003118 aryl group Chemical group 0.000 description 100
• 125000001072 heteroaryl group Chemical group 0.000 description 92
• 102000005962 receptors Human genes 0.000 description 92
• 108020003175 receptors Proteins 0.000 description 92
• 125000000623 heterocyclic group Chemical group 0.000 description 85
• 230000027455 binding Effects 0.000 description 84
• 125000003545 alkoxy group Chemical group 0.000 description 82
• 125000005843 halogen group Chemical group 0.000 description 76
• 239000003446 ligand Substances 0.000 description 75
• 208000035475 disorder Diseases 0.000 description 72
• 239000011541 reaction mixture Substances 0.000 description 68
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 66
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 65
• 239000000203 mixture Substances 0.000 description 61
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 61
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 61
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 57
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 56
• 125000000753 cycloalkyl group Chemical group 0.000 description 55
• 238000007429 general method Methods 0.000 description 55
• 210000004027 cell Anatomy 0.000 description 54
• 201000000980 schizophrenia Diseases 0.000 description 52
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 51
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 50
• 125000005102 carbonylalkoxy group Chemical group 0.000 description 49
• 208000024891 symptom Diseases 0.000 description 49
• 229940075993 receptor modulator Drugs 0.000 description 48
• 229940076279 serotonin Drugs 0.000 description 47
• 201000010099 disease Diseases 0.000 description 46
• 230000014511 neuron projection development Effects 0.000 description 46
• 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 45
• 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 45
• 238000003556 assay Methods 0.000 description 45
• 125000004442 acylamino group Chemical group 0.000 description 44
• 108060003345 Adrenergic Receptor Proteins 0.000 description 43
• 102000017910 Adrenergic receptor Human genes 0.000 description 43
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 41
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 40
• 239000005977 Ethylene Substances 0.000 description 40
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 39
• 125000003342 alkenyl group Chemical group 0.000 description 38
• 239000000243 solution Substances 0.000 description 38
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical class Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 37
• 102000015554 Dopamine receptor Human genes 0.000 description 36
• 108050004812 Dopamine receptor Proteins 0.000 description 36
• 239000000872 buffer Substances 0.000 description 35
• 230000002829 reductive effect Effects 0.000 description 35
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 34
• 125000000304 alkynyl group Chemical group 0.000 description 34
• 241000282414 Homo sapiens Species 0.000 description 33
• 239000005557 antagonist Substances 0.000 description 33
• 125000004423 acyloxy group Chemical group 0.000 description 32
• 239000000556 agonist Substances 0.000 description 32
• 235000019439 ethyl acetate Nutrition 0.000 description 32
• 125000003107 substituted aryl group Chemical group 0.000 description 32
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 30
• 125000004093 cyano group Chemical group *C#N 0.000 description 30
• 239000003981 vehicle Substances 0.000 description 30
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 29
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 29
• 125000000266 alpha-aminoacyl group Chemical group 0.000 description 29
• 230000005764 inhibitory process Effects 0.000 description 29
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
• 229910052799 carbon Inorganic materials 0.000 description 28
• 238000006243 chemical reaction Methods 0.000 description 28
• 238000011161 development Methods 0.000 description 28
• 230000018109 developmental process Effects 0.000 description 28
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 28
• 239000012044 organic layer Substances 0.000 description 28
• 125000002252 acyl group Chemical group 0.000 description 27
• 238000010256 biochemical assay Methods 0.000 description 27
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 26
• 210000002569 neuron Anatomy 0.000 description 25
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 24
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 24
• 125000003710 aryl alkyl group Chemical group 0.000 description 24
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 24
• 230000006870 function Effects 0.000 description 24
• 208000024827 Alzheimer disease Diseases 0.000 description 23
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 23
• 238000002360 preparation method Methods 0.000 description 23
• 125000004076 pyridyl group Chemical group 0.000 description 23
• 230000009870 specific binding Effects 0.000 description 23
• 125000004001 thioalkyl group Chemical group 0.000 description 23
• 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 description 22
• 230000007074 memory dysfunction Effects 0.000 description 22
• 230000009871 nonspecific binding Effects 0.000 description 22
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 21
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
• 125000004104 aryloxy group Chemical group 0.000 description 21
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 21
• 238000003653 radioligand binding assay Methods 0.000 description 21
• 125000000547 substituted alkyl group Chemical group 0.000 description 21
• 125000004432 carbon atom Chemical group C* 0.000 description 20
• 230000015654 memory Effects 0.000 description 20
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 20
• 238000003756 stirring Methods 0.000 description 20
• 230000000875 corresponding effect Effects 0.000 description 19
• 102100032509 Histamine H1 receptor Human genes 0.000 description 18
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 18
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
• 230000009286 beneficial effect Effects 0.000 description 18
• 229910052757 nitrogen Inorganic materials 0.000 description 18
• 238000010898 silica gel chromatography Methods 0.000 description 18
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 17
• 230000004064 dysfunction Effects 0.000 description 17
• 229960001340 histamine Drugs 0.000 description 17
• 239000000047 product Substances 0.000 description 17
• 241000700159 Rattus Species 0.000 description 16
• 125000005589 carbonylalkylenealkoxy group Chemical group 0.000 description 16
• 230000001713 cholinergic effect Effects 0.000 description 16
• 239000012043 crude product Substances 0.000 description 16
• 208000027061 mild cognitive impairment Diseases 0.000 description 16
• 230000010807 negative regulation of binding Effects 0.000 description 16
• 239000000741 silica gel Substances 0.000 description 16
• 229910002027 silica gel Inorganic materials 0.000 description 16
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 15
• 241001465754 Metazoa Species 0.000 description 15
• 230000001800 adrenalinergic effect Effects 0.000 description 15
• 230000004766 neurogenesis Effects 0.000 description 15
• 101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 description 14
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
• 230000003920 cognitive function Effects 0.000 description 14
• 125000000392 cycloalkenyl group Chemical group 0.000 description 14
• 230000014759 maintenance of location Effects 0.000 description 14
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
• 230000004044 response Effects 0.000 description 14
• 101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 13
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 13
• 230000015572 biosynthetic process Effects 0.000 description 13
• 239000012535 impurity Substances 0.000 description 13
• 210000001672 ovary Anatomy 0.000 description 13
• 238000004007 reversed phase HPLC Methods 0.000 description 13
• 229910000104 sodium hydride Inorganic materials 0.000 description 13
• 239000012453 solvate Substances 0.000 description 13
• 241000699802 Cricetulus griseus Species 0.000 description 12
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
• 210000004556 brain Anatomy 0.000 description 12
• 230000006735 deficit Effects 0.000 description 12
• 229960003638 dopamine Drugs 0.000 description 12
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 12
• 229910052701 rubidium Inorganic materials 0.000 description 12
• 208000020431 spinal cord injury Diseases 0.000 description 12
• 238000003786 synthesis reaction Methods 0.000 description 12
• 150000003573 thiols Chemical class 0.000 description 12
• 208000018737 Parkinson disease Diseases 0.000 description 11
• 125000001309 chloro group Chemical group Cl* 0.000 description 11
• 230000003247 decreasing effect Effects 0.000 description 11
• 229910052739 hydrogen Inorganic materials 0.000 description 11
• JNODQFNWMXFMEV-UHFFFAOYSA-N latrepirdine Chemical compound C1N(C)CCC2=C1C1=CC(C)=CC=C1N2CCC1=CC=C(C)N=C1 JNODQFNWMXFMEV-UHFFFAOYSA-N 0.000 description 11
• 230000000508 neurotrophic effect Effects 0.000 description 11
• 238000004366 reverse phase liquid chromatography Methods 0.000 description 11
• 125000001424 substituent group Chemical group 0.000 description 11
• 208000011580 syndromic disease Diseases 0.000 description 11
• 238000004809 thin layer chromatography Methods 0.000 description 11
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
• 208000030886 Traumatic Brain injury Diseases 0.000 description 10
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 10
• 125000005121 aminocarbonylalkoxy group Chemical group 0.000 description 10
• 230000006378 damage Effects 0.000 description 10
• 108010017146 dopamine D2L receptor Proteins 0.000 description 10
• 229940079593 drug Drugs 0.000 description 10
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 10
• 238000003818 flash chromatography Methods 0.000 description 10
• 230000006872 improvement Effects 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 208000014674 injury Diseases 0.000 description 10
• 206010027175 memory impairment Diseases 0.000 description 10
• 230000004770 neurodegeneration Effects 0.000 description 10
• 208000015122 neurodegenerative disease Diseases 0.000 description 10
• 230000007935 neutral effect Effects 0.000 description 10
• 230000003414 procognitive effect Effects 0.000 description 10
• 239000011780 sodium chloride Substances 0.000 description 10
• 125000005017 substituted alkenyl group Chemical group 0.000 description 10
• 230000009529 traumatic brain injury Effects 0.000 description 10
• 239000012981 Hank's balanced salt solution Substances 0.000 description 9
• 208000023105 Huntington disease Diseases 0.000 description 9
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
• 230000001149 cognitive effect Effects 0.000 description 9
• 230000034994 death Effects 0.000 description 9
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
• 239000012458 free base Substances 0.000 description 9
• 210000002161 motor neuron Anatomy 0.000 description 9
• 239000002904 solvent Substances 0.000 description 9
• 125000004426 substituted alkynyl group Chemical group 0.000 description 9
• 108091005435 5-HT6 receptors Proteins 0.000 description 8
• 102100032499 Histamine H2 receptor Human genes 0.000 description 8
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
• 230000002159 abnormal effect Effects 0.000 description 8
• 239000012267 brine Substances 0.000 description 8
• 239000000460 chlorine Substances 0.000 description 8
• 238000002648 combination therapy Methods 0.000 description 8
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 8
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
• 208000002780 macular degeneration Diseases 0.000 description 8
• 230000035772 mutation Effects 0.000 description 8
• 239000005022 packaging material Substances 0.000 description 8
• 230000008569 process Effects 0.000 description 8
• 230000009467 reduction Effects 0.000 description 8
• 229910052938 sodium sulfate Inorganic materials 0.000 description 8
• 235000011152 sodium sulphate Nutrition 0.000 description 8
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
• 239000000725 suspension Substances 0.000 description 8
• 210000000225 synapse Anatomy 0.000 description 8
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 238000002560 therapeutic procedure Methods 0.000 description 8
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
• 206010003805 Autism Diseases 0.000 description 7
• 208000020706 Autistic disease Diseases 0.000 description 7
• 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 7
• 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 7
• 241000282465 Canis Species 0.000 description 7
• 102100020756 D(2) dopamine receptor Human genes 0.000 description 7
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 7
• 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 7
• VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 7
• 208000006011 Stroke Diseases 0.000 description 7
• 208000027418 Wounds and injury Diseases 0.000 description 7
• 230000032683 aging Effects 0.000 description 7
• 125000002877 alkyl aryl group Chemical group 0.000 description 7
• 208000026935 allergic disease Diseases 0.000 description 7
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 7
• 230000006399 behavior Effects 0.000 description 7
• 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 7
• 238000002474 experimental method Methods 0.000 description 7
• 230000013016 learning Effects 0.000 description 7
• 229950002454 lysergide Drugs 0.000 description 7
• 238000005259 measurement Methods 0.000 description 7
• 201000006417 multiple sclerosis Diseases 0.000 description 7
• 210000003205 muscle Anatomy 0.000 description 7
• 230000008447 perception Effects 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 239000002953 phosphate buffered saline Substances 0.000 description 7
• 230000000750 progressive effect Effects 0.000 description 7
• 125000005415 substituted alkoxy group Chemical group 0.000 description 7
• 229940086542 triethylamine Drugs 0.000 description 7
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
• 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 6
• 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 6
• 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 6
• 208000020925 Bipolar disease Diseases 0.000 description 6
• 208000001640 Fibromyalgia Diseases 0.000 description 6
• 101001016827 Homo sapiens Histamine H2 receptor Proteins 0.000 description 6
• STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 6
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
• STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 6
• 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 6
• 230000000561 anti-psychotic effect Effects 0.000 description 6
• 229910052794 bromium Inorganic materials 0.000 description 6
• 210000003169 central nervous system Anatomy 0.000 description 6
• 238000004440 column chromatography Methods 0.000 description 6
• 239000013058 crude material Substances 0.000 description 6
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
• 231100000673 dose–response relationship Toxicity 0.000 description 6
• 238000002825 functional assay Methods 0.000 description 6
• 230000002068 genetic effect Effects 0.000 description 6
• 238000004128 high performance liquid chromatography Methods 0.000 description 6
• 208000013403 hyperactivity Diseases 0.000 description 6
• 238000011534 incubation Methods 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 125000004043 oxo group Chemical group O=* 0.000 description 6
• 208000033808 peripheral neuropathy Diseases 0.000 description 6
• 229960002429 proline Drugs 0.000 description 6
• 108090000623 proteins and genes Proteins 0.000 description 6
• STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 6
• 229960002646 scopolamine Drugs 0.000 description 6
• 239000000126 substance Substances 0.000 description 6
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 6
• VAYOSLLFUXYJDT-QZGBZKRISA-N (6ar,9r)-n,n-diethyl-7-(tritritiomethyl)-6,6a,8,9-tetrahydro-4h-indolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C([3H])([3H])[3H])C(=O)N(CC)CC)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-QZGBZKRISA-N 0.000 description 5
• LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
• 108091005436 5-HT7 receptors Proteins 0.000 description 5
• 201000004384 Alopecia Diseases 0.000 description 5
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 5
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 5
• 208000019901 Anxiety disease Diseases 0.000 description 5
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 5
• 108090001111 Dopamine D2 Receptors Proteins 0.000 description 5
• 102000004980 Dopamine D2 Receptors Human genes 0.000 description 5
• 239000007995 HEPES buffer Substances 0.000 description 5
• 108090000110 Histamine H1 Receptors Proteins 0.000 description 5
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
• 102000004108 Neurotransmitter Receptors Human genes 0.000 description 5
• 108090000590 Neurotransmitter Receptors Proteins 0.000 description 5
• 241000700157 Rattus norvegicus Species 0.000 description 5
• 150000001412 amines Chemical class 0.000 description 5
• 125000006598 aminocarbonylamino group Chemical group 0.000 description 5
• 230000036506 anxiety Effects 0.000 description 5
• 235000010323 ascorbic acid Nutrition 0.000 description 5
• 229960005070 ascorbic acid Drugs 0.000 description 5
• 239000011668 ascorbic acid Substances 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• 239000003795 chemical substances by application Substances 0.000 description 5
• 229910052801 chlorine Inorganic materials 0.000 description 5
• 230000019771 cognition Effects 0.000 description 5
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 5
• 230000001086 cytosolic effect Effects 0.000 description 5
• 230000006866 deterioration Effects 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 5
• 230000016273 neuron death Effects 0.000 description 5
• 201000001119 neuropathy Diseases 0.000 description 5
• 230000007823 neuropathy Effects 0.000 description 5
• 229920006395 saturated elastomer Polymers 0.000 description 5
• 230000001953 sensory effect Effects 0.000 description 5
• QGUXISBWKDNKGJ-UHFFFAOYSA-N 1-(1-bromoprop-1-en-2-yl)-4-fluorobenzene Chemical compound BrC=C(C)C1=CC=C(F)C=C1 QGUXISBWKDNKGJ-UHFFFAOYSA-N 0.000 description 4
• DKMAHJMVOVIJAA-UHFFFAOYSA-N 2,3,4,9,10,10a-hexahydro-1h-3a,8,9-triaza-cyclopenta[b]fluorene Chemical compound N1C2=NC=CC=C2C2=C1CC1CCCN1C2 DKMAHJMVOVIJAA-UHFFFAOYSA-N 0.000 description 4
• LMNPAYKJOZJLRU-UHFFFAOYSA-N 2-(6-methylpyridin-3-yl)ethyl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OCCC1=CC=C(C)N=C1 LMNPAYKJOZJLRU-UHFFFAOYSA-N 0.000 description 4
• NSWLMOHUXYULKL-UHFFFAOYSA-N 2-chloro-1-piperidin-1-ylethanone Chemical compound ClCC(=O)N1CCCCC1 NSWLMOHUXYULKL-UHFFFAOYSA-N 0.000 description 4
• AIHPVJCBRPRENO-UHFFFAOYSA-N 5-ethenyl-2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=C(C=C)C=N1 AIHPVJCBRPRENO-UHFFFAOYSA-N 0.000 description 4
• 208000028698 Cognitive impairment Diseases 0.000 description 4
• 229910021595 Copper(I) iodide Inorganic materials 0.000 description 4
• 241000282412 Homo Species 0.000 description 4
• 229930182821 L-proline Natural products 0.000 description 4
• 108010025020 Nerve Growth Factor Proteins 0.000 description 4
• 208000028389 Nerve injury Diseases 0.000 description 4
• 208000022873 Ocular disease Diseases 0.000 description 4
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 150000001350 alkyl halides Chemical class 0.000 description 4
• 230000003281 allosteric effect Effects 0.000 description 4
• 239000000739 antihistaminic agent Substances 0.000 description 4
• 239000011575 calcium Substances 0.000 description 4
• 230000002490 cerebral effect Effects 0.000 description 4
• LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 4
• 230000001054 cortical effect Effects 0.000 description 4
• 210000003618 cortical neuron Anatomy 0.000 description 4
• 239000013078 crystal Substances 0.000 description 4
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
• 230000002354 daily effect Effects 0.000 description 4
• 230000007423 decrease Effects 0.000 description 4
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
• 239000000835 fiber Substances 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• 150000002430 hydrocarbons Chemical group 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• FPCCSQOGAWCVBH-UHFFFAOYSA-N ketanserin Chemical compound C1=CC(F)=CC=C1C(=O)C1CCN(CCN2C(C3=CC=CC=C3NC2=O)=O)CC1 FPCCSQOGAWCVBH-UHFFFAOYSA-N 0.000 description 4
• 210000003734 kidney Anatomy 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 4
• 210000005036 nerve Anatomy 0.000 description 4
• 230000008764 nerve damage Effects 0.000 description 4
• 210000002241 neurite Anatomy 0.000 description 4
• 125000004433 nitrogen atom Chemical group N* 0.000 description 4
• 125000006574 non-aromatic ring group Chemical group 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 4
• 125000004193 piperazinyl group Chemical group 0.000 description 4
• 230000002035 prolonged effect Effects 0.000 description 4
• 208000020016 psychiatric disease Diseases 0.000 description 4
• 125000003373 pyrazinyl group Chemical group 0.000 description 4
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 238000002821 scintillation proximity assay Methods 0.000 description 4
• 239000011734 sodium Substances 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 239000011343 solid material Substances 0.000 description 4
• 125000005346 substituted cycloalkyl group Chemical group 0.000 description 4
• NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 4
• 210000001519 tissue Anatomy 0.000 description 4
• NNVUQTFSWSHHKU-UHFFFAOYSA-N 2,3,4,5,6,10c-hexahydro-1h-3a,6,7-triaza-cyclopenta[c]fluorene Chemical compound N1C2=NC=CC=C2C2=C1CCN1C2CCC1 NNVUQTFSWSHHKU-UHFFFAOYSA-N 0.000 description 3
• DNYBLNHCXCSJFB-UHFFFAOYSA-N 3-methyl-7,8,9,9a,10,11-hexahydro-5h-pyrido[3',2':4,5]pyrrolo[3,2-f]indolizine Chemical compound C1C2CCCN2CC2=C1NC1=NC=C(C)C=C12 DNYBLNHCXCSJFB-UHFFFAOYSA-N 0.000 description 3
• KRROYLIDJBSPDW-UHFFFAOYSA-N 4-(oxiran-2-yl)pyridine Chemical compound C1OC1C1=CC=NC=C1 KRROYLIDJBSPDW-UHFFFAOYSA-N 0.000 description 3
• VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical class O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 108010011485 Aspartame Proteins 0.000 description 3
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
• 241000282472 Canis lupus familiaris Species 0.000 description 3
• 208000002177 Cataract Diseases 0.000 description 3
• 206010012289 Dementia Diseases 0.000 description 3
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
• 208000004262 Food Hypersensitivity Diseases 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 229930091371 Fructose Natural products 0.000 description 3
• 239000005715 Fructose Substances 0.000 description 3
• RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• 206010020751 Hypersensitivity Diseases 0.000 description 3
• 239000005913 Maltodextrin Substances 0.000 description 3
• 229920002774 Maltodextrin Polymers 0.000 description 3
• 229910003827 NRaRb Inorganic materials 0.000 description 3
• 102000015336 Nerve Growth Factor Human genes 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 241000288906 Primates Species 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• 229930006000 Sucrose Natural products 0.000 description 3
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
• 239000000654 additive Substances 0.000 description 3
• 230000000996 additive effect Effects 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 231100000360 alopecia Toxicity 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 3
• 239000000605 aspartame Substances 0.000 description 3
• 235000010357 aspartame Nutrition 0.000 description 3
• 229960003438 aspartame Drugs 0.000 description 3
• 230000003935 attention Effects 0.000 description 3
• 210000003050 axon Anatomy 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
• 230000004071 biological effect Effects 0.000 description 3
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 125000002837 carbocyclic group Chemical group 0.000 description 3
• 150000001721 carbon Chemical group 0.000 description 3
• 238000004587 chromatography analysis Methods 0.000 description 3
• 229940125904 compound 1 Drugs 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 239000008121 dextrose Substances 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 230000002708 enhancing effect Effects 0.000 description 3
• 239000012091 fetal bovine serum Substances 0.000 description 3
• 125000001153 fluoro group Chemical group F* 0.000 description 3
• 235000020932 food allergy Nutrition 0.000 description 3
• 125000002541 furyl group Chemical group 0.000 description 3
• 230000002398 geroprotective effect Effects 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 125000005842 heteroatom Chemical group 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• HPMRFMKYPGXPEP-UHFFFAOYSA-N idazoxan Chemical compound N1CCN=C1C1OC2=CC=CC=C2OC1 HPMRFMKYPGXPEP-UHFFFAOYSA-N 0.000 description 3
• 229950001476 idazoxan Drugs 0.000 description 3
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
• 210000000987 immune system Anatomy 0.000 description 3
• 230000003993 interaction Effects 0.000 description 3
• 150000002500 ions Chemical class 0.000 description 3
• 230000002427 irreversible effect Effects 0.000 description 3
• 229960005417 ketanserin Drugs 0.000 description 3
• 230000006742 locomotor activity Effects 0.000 description 3
• 229940035034 maltodextrin Drugs 0.000 description 3
• 210000003470 mitochondria Anatomy 0.000 description 3
• 230000004065 mitochondrial dysfunction Effects 0.000 description 3
• 229940053128 nerve growth factor Drugs 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 230000003955 neuronal function Effects 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 150000007530 organic bases Chemical class 0.000 description 3
• 230000007170 pathology Effects 0.000 description 3
• MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 3
• 229960001999 phentolamine Drugs 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
• 238000007634 remodeling Methods 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 230000004936 stimulating effect Effects 0.000 description 3
• 239000005720 sucrose Substances 0.000 description 3
• 230000008733 trauma Effects 0.000 description 3
• 210000004885 white matter Anatomy 0.000 description 3
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 2
• FLRUNCJXOVYWDH-UHFFFAOYSA-N 1-(2-bromoethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CCBr)C=C1 FLRUNCJXOVYWDH-UHFFFAOYSA-N 0.000 description 2
• UDAYANJJWPYDRG-UHFFFAOYSA-N 10-chloro-2,3,5,6,7,11c-hexahydro-1h-indolizino[7,8-b]indole Chemical compound C1CN2CCCC2C2=C1NC1=CC=C(Cl)C=C12 UDAYANJJWPYDRG-UHFFFAOYSA-N 0.000 description 2
• ASDVKHNYOLEEBX-UHFFFAOYSA-N 10-methyl-2,3,5,6,7,11c-hexahydro-1h-indolizino[7,8-b]indole Chemical compound C1CN2CCCC2C2=C1NC1=CC=C(C)C=C12 ASDVKHNYOLEEBX-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• QXIUMMLTJVHILT-UHFFFAOYSA-N 4-[3-(tert-butylamino)-2-hydroxypropoxy]-1H-indole-2-carbonitrile Chemical compound CC(C)(C)NCC(O)COC1=CC=CC2=C1C=C(C#N)N2 QXIUMMLTJVHILT-UHFFFAOYSA-N 0.000 description 2
• 229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 2
• 102000006902 5-HT2C Serotonin Receptor Human genes 0.000 description 2
• 108010072553 5-HT2C Serotonin Receptor Proteins 0.000 description 2
• 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
• 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
• 102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 2
• 101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 2
• 102100040370 5-hydroxytryptamine receptor 5A Human genes 0.000 description 2
• 101710138069 5-hydroxytryptamine receptor 5A Proteins 0.000 description 2
• HHSXXLHQLGBVHD-UHFFFAOYSA-N 7-chloro-2,3,5,10,11,11a-hexahydro-1h-indolizino[7,6-b]indole Chemical compound C1C2CCCN2CC2=C1NC1=CC=C(Cl)C=C12 HHSXXLHQLGBVHD-UHFFFAOYSA-N 0.000 description 2
• ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
• IKQNICMCGVCWLC-UHFFFAOYSA-N 9-methyl-2,3,4,5,6,10c-hexahydro-1h-3a,6,7-triaza-cyclopenta[c]fluorene Chemical compound C1CN2CCCC2C2=C1NC1=NC=C(C)C=C12 IKQNICMCGVCWLC-UHFFFAOYSA-N 0.000 description 2
• 101150051188 Adora2a gene Proteins 0.000 description 2
• 101150078577 Adora2b gene Proteins 0.000 description 2
• 208000037259 Amyloid Plaque Diseases 0.000 description 2
• 208000036640 Asperger disease Diseases 0.000 description 2
• 201000006062 Asperger syndrome Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 208000017667 Chronic Disease Diseases 0.000 description 2
• 206010012239 Delusion Diseases 0.000 description 2
• 208000003164 Diplopia Diseases 0.000 description 2
• 241000283073 Equus caballus Species 0.000 description 2
• 229920002148 Gellan gum Polymers 0.000 description 2
• 208000004547 Hallucinations Diseases 0.000 description 2
• 108090000050 Histamine H2 Receptors Proteins 0.000 description 2
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 2
• 102000016252 Huntingtin Human genes 0.000 description 2
• 108050004784 Huntingtin Proteins 0.000 description 2
• 102000009032 Imidazoline Receptors Human genes 0.000 description 2
• 108010049134 Imidazoline Receptors Proteins 0.000 description 2
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000026139 Memory disease Diseases 0.000 description 2
• VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
• UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• 206010028980 Neoplasm Diseases 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• 229920005372 Plexiglas® Polymers 0.000 description 2
• 206010036105 Polyneuropathy Diseases 0.000 description 2
• 208000008348 Post-Concussion Syndrome Diseases 0.000 description 2
• 108010050254 Presenilins Proteins 0.000 description 2
• 208000032319 Primary lateral sclerosis Diseases 0.000 description 2
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
• NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 2
• 208000006289 Rett Syndrome Diseases 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 206010044565 Tremor Diseases 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 239000004480 active ingredient Substances 0.000 description 2
• 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
• 238000011226 adjuvant chemotherapy Methods 0.000 description 2
• 125000002947 alkylene group Chemical group 0.000 description 2
• 150000001408 amides Chemical class 0.000 description 2
• CICDSYWWNDGAGD-UHFFFAOYSA-N aminopotentidine Chemical compound C1=CC(N)=CC=C1C(=O)NCCNC(NC#N)=NCCCOC1=CC=CC(CN2CCCCC2)=C1 CICDSYWWNDGAGD-UHFFFAOYSA-N 0.000 description 2
• 238000000540 analysis of variance Methods 0.000 description 2
• 229940124623 antihistamine drug Drugs 0.000 description 2
• 229940125715 antihistaminic agent Drugs 0.000 description 2
• 239000003420 antiserotonin agent Substances 0.000 description 2
• 101150031224 app gene Proteins 0.000 description 2
• 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
• 208000029560 autism spectrum disease Diseases 0.000 description 2
• 210000004227 basal ganglia Anatomy 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 208000013404 behavioral symptom Diseases 0.000 description 2
• 230000003542 behavioural effect Effects 0.000 description 2
• BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 2
• 239000011230 binding agent Substances 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 229910000019 calcium carbonate Inorganic materials 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 235000010418 carrageenan Nutrition 0.000 description 2
• 229920001525 carrageenan Polymers 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 210000003710 cerebral cortex Anatomy 0.000 description 2
• 239000007910 chewable tablet Substances 0.000 description 2
• 230000001055 chewing effect Effects 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 238000004891 communication Methods 0.000 description 2
• 230000006854 communication Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 125000004122 cyclic group Chemical group 0.000 description 2
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
• 230000003412 degenerative effect Effects 0.000 description 2
• 231100000868 delusion Toxicity 0.000 description 2
• 210000001787 dendrite Anatomy 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
• 239000007884 disintegrant Substances 0.000 description 2
• 229960003530 donepezil Drugs 0.000 description 2
• 230000003291 dopaminomimetic effect Effects 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 238000005538 encapsulation Methods 0.000 description 2
• 230000007613 environmental effect Effects 0.000 description 2
• GWQVMPWSEVRGPY-UHFFFAOYSA-N europium cryptate Chemical compound [Eu+3].N=1C2=CC=CC=1CN(CC=1N=C(C=CC=1)C=1N=C(C3)C=CC=1)CC(N=1)=CC(C(=O)NCCN)=CC=1C(N=1)=CC(C(=O)NCCN)=CC=1CN3CC1=CC=CC2=N1 GWQVMPWSEVRGPY-UHFFFAOYSA-N 0.000 description 2
• 229910052731 fluorine Inorganic materials 0.000 description 2
• 235000003599 food sweetener Nutrition 0.000 description 2
• 235000010492 gellan gum Nutrition 0.000 description 2
• 239000000216 gellan gum Substances 0.000 description 2
• 239000003349 gelling agent Substances 0.000 description 2
• 208000024963 hair loss Diseases 0.000 description 2
• 230000003676 hair loss Effects 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 230000002008 hemorrhagic effect Effects 0.000 description 2
• 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 2
• 150000002429 hydrazines Chemical class 0.000 description 2
• 125000002883 imidazolyl group Chemical group 0.000 description 2
• 230000001771 impaired effect Effects 0.000 description 2
• KPYKFQNTASVHIG-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CC2=C=C[CH]N21 KPYKFQNTASVHIG-UHFFFAOYSA-N 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 229910052740 iodine Inorganic materials 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 201000010901 lateral sclerosis Diseases 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 239000006210 lotion Substances 0.000 description 2
• 239000000314 lubricant Substances 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000003550 marker Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 229960000582 mepyramine Drugs 0.000 description 2
• 229960003955 mianserin Drugs 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 229940016286 microcrystalline cellulose Drugs 0.000 description 2
• 150000007522 mineralic acids Chemical class 0.000 description 2
• 230000004898 mitochondrial function Effects 0.000 description 2
• 150000004682 monohydrates Chemical class 0.000 description 2
• 201000005518 mononeuropathy Diseases 0.000 description 2
• 125000002757 morpholinyl group Chemical group 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 238000003522 neurite outgrowth assay Methods 0.000 description 2
• 210000000715 neuromuscular junction Anatomy 0.000 description 2
• 230000005015 neuronal process Effects 0.000 description 2
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
• 229960002748 norepinephrine Drugs 0.000 description 2
• 210000004248 oligodendroglia Anatomy 0.000 description 2
• 150000007524 organic acids Chemical class 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• 239000001301 oxygen Substances 0.000 description 2
• 229960001779 pargyline Drugs 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
• 230000007824 polyneuropathy Effects 0.000 description 2
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
• DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
• 229960003081 probenecid Drugs 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 201000008752 progressive muscular atrophy Diseases 0.000 description 2
• 102000004169 proteins and genes Human genes 0.000 description 2
• 201000003004 ptosis Diseases 0.000 description 2
• 125000000714 pyrimidinyl group Chemical group 0.000 description 2
• 125000000168 pyrrolyl group Chemical group 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• BLGXFZZNTVWLAY-DIRVCLHFSA-N rauwolscine Chemical compound C1=CC=C2C(CCN3C[C@H]4CC[C@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-DIRVCLHFSA-N 0.000 description 2
• 229940044601 receptor agonist Drugs 0.000 description 2
• 239000000018 receptor agonist Substances 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 230000003989 repetitive behavior Effects 0.000 description 2
• 208000013406 repetitive behavior Diseases 0.000 description 2
• 230000029058 respiratory gaseous exchange Effects 0.000 description 2
• 229910052702 rhenium Inorganic materials 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 2
• 230000035807 sensation Effects 0.000 description 2
• 239000000952 serotonin receptor agonist Substances 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 230000006403 short-term memory Effects 0.000 description 2
• 230000008454 sleep-wake cycle Effects 0.000 description 2
• 230000003997 social interaction Effects 0.000 description 2
• 239000008109 sodium starch glycolate Substances 0.000 description 2
• 229920003109 sodium starch glycolate Polymers 0.000 description 2
• 229940079832 sodium starch glycolate Drugs 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
• 125000003003 spiro group Chemical group 0.000 description 2
• 230000002269 spontaneous effect Effects 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 210000000130 stem cell Anatomy 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 239000011593 sulfur Substances 0.000 description 2
• 230000004083 survival effect Effects 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000009747 swallowing Effects 0.000 description 2
• 239000003765 sweetening agent Substances 0.000 description 2
• 230000002195 synergetic effect Effects 0.000 description 2
• 238000010189 synthetic method Methods 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• 230000008448 thought Effects 0.000 description 2
• 238000012549 training Methods 0.000 description 2
• 238000012546 transfer Methods 0.000 description 2
• 102000035160 transmembrane proteins Human genes 0.000 description 2
• 108091005703 transmembrane proteins Proteins 0.000 description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
• LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
• QQXLDOJGLXJCSE-KNVOCYPGSA-N tropinone Chemical compound C1C(=O)C[C@H]2CC[C@@H]1N2C QQXLDOJGLXJCSE-KNVOCYPGSA-N 0.000 description 2
• 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
• 230000004584 weight gain Effects 0.000 description 2
• 235000019786 weight gain Nutrition 0.000 description 2
• 230000004580 weight loss Effects 0.000 description 2
• 238000005550 wet granulation Methods 0.000 description 2
• 239000000230 xanthan gum Substances 0.000 description 2
• 229920001285 xanthan gum Polymers 0.000 description 2
• 235000010493 xanthan gum Nutrition 0.000 description 2
• 229940082509 xanthan gum Drugs 0.000 description 2
• JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
• JRDUBBHIPPPSLP-NFEZXYISSA-N (2R,12bR)-3'-methyl-1'-(tritritiomethyl)spiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,4'-1,3-diazinane]-2'-one Chemical compound [3H]C([3H])([3H])N1CC[C@@]2(CCN3CCc4c(oc5ccccc45)[C@H]3C2)N(C)C1=O JRDUBBHIPPPSLP-NFEZXYISSA-N 0.000 description 1
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
• WYCMFCPHWDZHMR-UHFFFAOYSA-N 1-(4,7-dimethyl-6,6a,8,9,10,10a-hexahydroindolo[4,3-fg]quinoline-9-yl)-n,n-dimethylmethanesulfonamide Chemical compound C1=CC(C2CC(CN(C)C2C2)CS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 WYCMFCPHWDZHMR-UHFFFAOYSA-N 0.000 description 1
• SKECWRUVOSXYAU-UHFFFAOYSA-N 1-(piperidin-1-yl)-2-(8,9,9a,10-tetrahydro-5h-pyrido[3',2':4,5]pyrrolo[3,2-f]indolizin-11(7h)-yl)ethanone Chemical compound C1=2CC3CCCN3CC=2C2=CC=CN=C2N1CC(=O)N1CCCCC1 SKECWRUVOSXYAU-UHFFFAOYSA-N 0.000 description 1
• YDDXVAXDYKBWDX-UHFFFAOYSA-N 1-cyano-3-[2-[[2-(diaminomethylideneamino)-4-thiazolyl]methylthio]ethyl]-2-methylguanidine Chemical compound N#CNC(=NC)NCCSCC1=CSC(N=C(N)N)=N1 YDDXVAXDYKBWDX-UHFFFAOYSA-N 0.000 description 1
• VYKBUGNWAJLELT-UHFFFAOYSA-N 10-methyl-7-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-2,3,5,6,7,11c-hexahydro-1h-pyrido[3',2':4,5]pyrrolo[2,3-g]indolizine Chemical compound C1=2CCN3CCCC3C=2C2=CC(C)=CN=C2N1CCC1=CC=C(C(F)(F)F)N=C1 VYKBUGNWAJLELT-UHFFFAOYSA-N 0.000 description 1
• AOJILXSEXSWBOE-UHFFFAOYSA-N 10-methyl-7-(2-(6-methylpyridin-3-yl)ethyl)-2,3,5,6,7,11c-hexahydro-1h-pyrido[3',2':4,5]pyrrolo[2,3-g]indolizine Chemical compound C1=2CCN3CCCC3C=2C2=CC(C)=CN=C2N1CCC1=CC=C(C)N=C1 AOJILXSEXSWBOE-UHFFFAOYSA-N 0.000 description 1
• KRQRLEBPIZVJRT-UHFFFAOYSA-N 106531-35-5 Chemical compound C12=NC=CC=C2C(=S)N=C2N1C=CS2 KRQRLEBPIZVJRT-UHFFFAOYSA-N 0.000 description 1
• IQBJPNGKXBNVRJ-UHFFFAOYSA-N 11-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-7,8,9,9a,10,11-hexahydro-5h-pyrido[3',2':4,5]pyrrolo[3,2-f]indolizine Chemical compound C1=NC(C(F)(F)F)=CC=C1CCN1C2=NC=CC=C2C(C2)=C1CC1N2CCC1 IQBJPNGKXBNVRJ-UHFFFAOYSA-N 0.000 description 1
• ONLAECAXYMAHIH-UHFFFAOYSA-N 11-(2-(6-methylpyridin-3-yl)ethyl)-7,8,9,9a,10,11-hexahydro-5h-pyrido[3',2':4,5]pyrrolo[3,2-f]indolizine Chemical compound C1=NC(C)=CC=C1CCN1C2=NC=CC=C2C(C2)=C1CC1N2CCC1 ONLAECAXYMAHIH-UHFFFAOYSA-N 0.000 description 1
• RAMVLMQLZWNAJR-UHFFFAOYSA-N 11-methyl-1,2,3,4,6,7,7a,8,12b,12c-decahydroindolo[3,2-a]quinolizine Chemical compound C1CN2CCCCC2C2C1NC1=CC=C(C)C=C12 RAMVLMQLZWNAJR-UHFFFAOYSA-N 0.000 description 1
• HOUDBBQXFPPDCP-UHFFFAOYSA-N 2-(3-methyl-8,9,9a,10-tetrahydro-5h-pyrido[3',2':4,5]pyrrolo[3,2-f]indolizin-11(7h)-yl)-1-(piperidin-1-yl)ethanone Chemical compound C1=2CC3CCCN3CC=2C2=CC(C)=CN=C2N1CC(=O)N1CCCCC1 HOUDBBQXFPPDCP-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• XQEXAEXSVHGTMD-UHFFFAOYSA-N 2-methyl-5,6,6a,7,8,9,10,12-octahydroindolo[2,3-b]quinolizine Chemical compound C1C2CCCCN2CC2=C1NC1=CC=C(C)C=C12 XQEXAEXSVHGTMD-UHFFFAOYSA-N 0.000 description 1
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
• KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical class C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
• XUSNPFGLKGCWGN-UHFFFAOYSA-N 3-[4-(3-aminopropyl)piperazin-1-yl]propan-1-amine Chemical compound NCCCN1CCN(CCCN)CC1 XUSNPFGLKGCWGN-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
• KOHWWLQYLWHHQR-UHFFFAOYSA-N 5-(1-bromoprop-1-en-2-yl)-2-methylpyridine Chemical compound BrC=C(C)C1=CC=C(C)N=C1 KOHWWLQYLWHHQR-UHFFFAOYSA-N 0.000 description 1
• 102000006969 5-HT2B Serotonin Receptor Human genes 0.000 description 1
• 108010072584 5-HT2B Serotonin Receptor Proteins 0.000 description 1
• 108091005477 5-HT3 receptors Proteins 0.000 description 1
• 102000035037 5-HT3 receptors Human genes 0.000 description 1
• 108091005482 5-HT4 receptors Proteins 0.000 description 1
• 229940124801 5-HT6 antagonist Drugs 0.000 description 1
• WLKFAHPMRMKTSB-UHFFFAOYSA-N 5-[2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-6,8,15-triazatetracyclo[7.7.0.02,7.011,15]hexadeca-1(9),2(7),3,5-tetraene Chemical compound FC(C1=CC=C(C=N1)CCC=1C=CC2=C(NC3=C2CN2CCCC2C3)N1)(F)F WLKFAHPMRMKTSB-UHFFFAOYSA-N 0.000 description 1
• 102100027499 5-hydroxytryptamine receptor 1B Human genes 0.000 description 1
• 101710138639 5-hydroxytryptamine receptor 1B Proteins 0.000 description 1
• SPBDQIQOMJATCG-UHFFFAOYSA-N 6-chloro-2,3,4,9,10,10a-hexahydro-1h-3a,8,9-triaza-cyclopenta[b]fluorene Chemical compound C1C2CCCN2CC2=C1NC1=NC=C(Cl)C=C12 SPBDQIQOMJATCG-UHFFFAOYSA-N 0.000 description 1
• IUEBFVUXWGRHRW-UHFFFAOYSA-N 7-(2-(6-(trifluoromethyl)pyridin-3-yl)ethyl)-2,3,5,6,7,11c-hexahydro-1h-pyrido[3',2':4,5]pyrrolo[2,3-g]indolizine Chemical compound C1=NC(C(F)(F)F)=CC=C1CCN1C2=NC=CC=C2C2=C1CCN1C2CCC1 IUEBFVUXWGRHRW-UHFFFAOYSA-N 0.000 description 1
• GHHAKQIYNBLNNG-UHFFFAOYSA-N 7-(2-(6-methylpyridin-3-yl)ethyl)-2,3,5,6,7,11c-hexahydro-1h-pyrido[3',2':4,5]pyrrolo[2,3-g]indolizine Chemical compound C1=NC(C)=CC=C1CCN1C2=NC=CC=C2C2=C1CCN1C2CCC1 GHHAKQIYNBLNNG-UHFFFAOYSA-N 0.000 description 1
• LEJBDKGXRCMFKH-UHFFFAOYSA-N 7-methyl-2,3,5,10,11,11a-hexahydro-1h-indolizino[7,6-b]indole Chemical compound C1C2CCCN2CC2=C1NC1=CC=C(C)C=C12 LEJBDKGXRCMFKH-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 206010000117 Abnormal behaviour Diseases 0.000 description 1
• 208000006888 Agnosia Diseases 0.000 description 1
• 239000012109 Alexa Fluor 568 Substances 0.000 description 1
• 108700028369 Alleles Proteins 0.000 description 1
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
• 208000000044 Amnesia Diseases 0.000 description 1
• 206010002027 Amyotrophy Diseases 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
• 206010003062 Apraxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000025978 Athletic injury Diseases 0.000 description 1
• 206010061666 Autonomic neuropathy Diseases 0.000 description 1
• 208000037663 Best vitelliform macular dystrophy Diseases 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 241000283690 Bos taurus Species 0.000 description 1
• 206010006100 Bradykinesia Diseases 0.000 description 1
• 208000014644 Brain disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• 239000004215 Carbon black (E152) Substances 0.000 description 1
• 241000700199 Cavia porcellus Species 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 208000027104 Chemotherapy-Related Cognitive Impairment Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• 108010009685 Cholinergic Receptors Proteins 0.000 description 1
• 206010008748 Chorea Diseases 0.000 description 1
• 206010009696 Clumsiness Diseases 0.000 description 1
• 206010009848 Cogwheel rigidity Diseases 0.000 description 1
• 208000006992 Color Vision Defects Diseases 0.000 description 1
• 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
• 241000699800 Cricetinae Species 0.000 description 1
• 229920002785 Croscarmellose sodium Polymers 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• 201000004624 Dermatitis Diseases 0.000 description 1
• 206010012559 Developmental delay Diseases 0.000 description 1
• 208000012239 Developmental disease Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 206010061818 Disease progression Diseases 0.000 description 1
• 206010013486 Distractibility Diseases 0.000 description 1
• 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
• 229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
• 201000001353 Doyne honeycomb retinal dystrophy Diseases 0.000 description 1
• 206010052804 Drug tolerance Diseases 0.000 description 1
• 206010052805 Drug tolerance decreased Diseases 0.000 description 1
• 206010013887 Dysarthria Diseases 0.000 description 1
• 208000012661 Dyskinesia Diseases 0.000 description 1
• 206010013976 Dyspraxia Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 101100108562 Escherichia coli (strain K12) aldA gene Proteins 0.000 description 1
• 239000001856 Ethyl cellulose Substances 0.000 description 1
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
• 206010015995 Eyelid ptosis Diseases 0.000 description 1
• 208000013171 Fahr disease Diseases 0.000 description 1
• 208000037312 Familial drusen Diseases 0.000 description 1
• 208000001308 Fasciculation Diseases 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108091006027 G proteins Proteins 0.000 description 1
• 102000030782 GTP binding Human genes 0.000 description 1
• 108091000058 GTP-Binding Proteins 0.000 description 1
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
• 229930182566 Gentamicin Natural products 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
• WGCNASOHLSPBMP-UHFFFAOYSA-N Glycolaldehyde Chemical compound OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
• 206010019196 Head injury Diseases 0.000 description 1
• 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
• 208000007514 Herpes zoster Diseases 0.000 description 1
• 102000004384 Histamine H3 receptors Human genes 0.000 description 1
• 108090000981 Histamine H3 receptors Proteins 0.000 description 1
• 229940123322 Histamine receptor agonist Drugs 0.000 description 1
• 229940122236 Histamine receptor antagonist Drugs 0.000 description 1
• 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
• 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 1
• 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 1
• 241000257303 Hymenoptera Species 0.000 description 1
• 208000035150 Hypercholesterolemia Diseases 0.000 description 1
• 208000006083 Hypokinesia Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 208000032578 Inherited retinal disease Diseases 0.000 description 1
• 208000015592 Involuntary movements Diseases 0.000 description 1
• 206010022998 Irritability Diseases 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• 201000003533 Leber congenital amaurosis Diseases 0.000 description 1
• 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
• 208000009829 Lewy Body Disease Diseases 0.000 description 1
• 201000002832 Lewy body dementia Diseases 0.000 description 1
• 208000016604 Lyme disease Diseases 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
• 208000012583 Menkes disease Diseases 0.000 description 1
• JLVHTNZNKOSCNB-YSVLISHTSA-N Mesulergine Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CN(C)C3=C1 JLVHTNZNKOSCNB-YSVLISHTSA-N 0.000 description 1
• RLJFTICUTYVZDG-UHFFFAOYSA-N Methiothepine Chemical group C12=CC(SC)=CC=C2SC2=CC=CC=C2CC1N1CCN(C)CC1 RLJFTICUTYVZDG-UHFFFAOYSA-N 0.000 description 1
• 102100021118 Microtubule-associated protein 2 Human genes 0.000 description 1
• 206010027918 Mononeuropathy multiplex Diseases 0.000 description 1
• 101100054327 Mus musculus Abcd1 gene Proteins 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 208000002740 Muscle Rigidity Diseases 0.000 description 1
• 206010028347 Muscle twitching Diseases 0.000 description 1
• KAHMEWANVDFFCQ-UHFFFAOYSA-N N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-(2,6-dimethoxyphenoxy)ethanamine hydrochloride Chemical compound Cl.COC1=CC=CC(OC)=C1OCCNCC1OC2=CC=CC=C2OC1 KAHMEWANVDFFCQ-UHFFFAOYSA-N 0.000 description 1
• WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
• QQXLDOJGLXJCSE-UHFFFAOYSA-N N-methylnortropinone Natural products C1C(=O)CC2CCC1N2C QQXLDOJGLXJCSE-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 108020001305 NR1 subfamily Proteins 0.000 description 1
• 239000007832 Na2SO4 Substances 0.000 description 1
• 102000007072 Nerve Growth Factors Human genes 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
• 208000016113 North Carolina macular dystrophy Diseases 0.000 description 1
• 208000013661 Oguchi disease Diseases 0.000 description 1
• 206010061323 Optic neuropathy Diseases 0.000 description 1
• 206010053159 Organ failure Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 208000034247 Pattern dystrophy Diseases 0.000 description 1
• 208000028361 Penetrating Head injury Diseases 0.000 description 1
• 206010034719 Personality change Diseases 0.000 description 1
• 239000004743 Polypropylene Substances 0.000 description 1
• 206010067206 Postural reflex impairment Diseases 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
• 206010037779 Radiculopathy Diseases 0.000 description 1
• 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 206010039897 Sedation Diseases 0.000 description 1
• 206010040030 Sensory loss Diseases 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 206010041349 Somnolence Diseases 0.000 description 1
• 208000022758 Sorsby fundus dystrophy Diseases 0.000 description 1
• 208000014604 Specific Language disease Diseases 0.000 description 1
• 201000010829 Spina bifida Diseases 0.000 description 1
• 208000006097 Spinal Dysraphism Diseases 0.000 description 1
• 229920002472 Starch Polymers 0.000 description 1
• 208000027073 Stargardt disease Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• 102000019355 Synuclein Human genes 0.000 description 1
• 108050006783 Synuclein Proteins 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 206010043431 Thinking abnormal Diseases 0.000 description 1
• 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
• 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
• GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 102000004243 Tubulin Human genes 0.000 description 1
• 108090000704 Tubulin Proteins 0.000 description 1
• 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 208000014769 Usher Syndromes Diseases 0.000 description 1
• 241000256856 Vespidae Species 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• 238000002441 X-ray diffraction Methods 0.000 description 1
• DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
• MOZPSIXKYJUTKI-RLXJOQACSA-N [1-[2-(methanesulfonamido)ethyl]piperidin-4-yl]methyl 1-(tritritiomethyl)indole-3-carboxylate Chemical compound C12=CC=CC=C2N(C([3H])([3H])[3H])C=C1C(=O)OCC1CCN(CCNS(C)(=O)=O)CC1 MOZPSIXKYJUTKI-RLXJOQACSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 102000034337 acetylcholine receptors Human genes 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 208000037919 acquired disease Diseases 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 239000000048 adrenergic agonist Substances 0.000 description 1
• 239000000674 adrenergic antagonist Substances 0.000 description 1
• 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
• 125000003158 alcohol group Chemical group 0.000 description 1
• 101150049512 ald gene Proteins 0.000 description 1
• 229910001413 alkali metal ion Inorganic materials 0.000 description 1
• 150000001336 alkenes Chemical class 0.000 description 1
• 125000003302 alkenyloxy group Chemical group 0.000 description 1
• 125000005133 alkynyloxy group Chemical group 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 230000004075 alteration Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000008485 antagonism Effects 0.000 description 1
• 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000001363 autoimmune Effects 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 210000002453 autonomic neuron Anatomy 0.000 description 1
• 201000002922 basal ganglia calcification Diseases 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 210000003651 basophil Anatomy 0.000 description 1
• 231100000871 behavioral problem Toxicity 0.000 description 1
• MNJNPLVXBISNSX-WDNDVIMCSA-N bemesetron Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C1=CC(Cl)=CC(Cl)=C1 MNJNPLVXBISNSX-WDNDVIMCSA-N 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 208000016791 bilateral striopallidodentate calcinosis Diseases 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
• 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
• 238000004820 blood count Methods 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 230000004641 brain development Effects 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 210000001775 bruch membrane Anatomy 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 230000003491 cAMP production Effects 0.000 description 1
• 229960003563 calcium carbonate Drugs 0.000 description 1
• AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
• 239000000920 calcium hydroxide Substances 0.000 description 1
• 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
• 239000000679 carrageenan Substances 0.000 description 1
• 229940113118 carrageenan Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 206010007776 catatonia Diseases 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010267 cellular communication Effects 0.000 description 1
• 230000004637 cellular stress Effects 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000003153 chemical reaction reagent Substances 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• VXIVSQZSERGHQP-UHFFFAOYSA-N chloroacetamide Chemical group NC(=O)CCl VXIVSQZSERGHQP-UHFFFAOYSA-N 0.000 description 1
• 239000000812 cholinergic antagonist Substances 0.000 description 1
• 208000012601 choreatic disease Diseases 0.000 description 1
• 210000003161 choroid Anatomy 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 239000011248 coating agent Substances 0.000 description 1
• 230000007278 cognition impairment Effects 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 230000037411 cognitive enhancing Effects 0.000 description 1
• 230000036992 cognitive tasks Effects 0.000 description 1
• 201000007254 color blindness Diseases 0.000 description 1
• 238000012875 competitive assay Methods 0.000 description 1
• 231100000867 compulsive behavior Toxicity 0.000 description 1
• 208000006623 congenital stationary night blindness Diseases 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 229910000365 copper sulfate Inorganic materials 0.000 description 1
• ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
• GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
• 229960001681 croscarmellose sodium Drugs 0.000 description 1
• 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
• 239000002619 cytotoxin Substances 0.000 description 1
• 125000005508 decahydronaphthalenyl group Chemical group 0.000 description 1
• 206010061428 decreased appetite Diseases 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 230000002939 deleterious effect Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 206010012601 diabetes mellitus Diseases 0.000 description 1
• 238000003796 diagnosis of exclusion Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• 125000004982 dihaloalkyl group Chemical group 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 230000005750 disease progression Effects 0.000 description 1
• 239000003210 dopamine receptor blocking agent Substances 0.000 description 1
• 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
• 210000005064 dopaminergic neuron Anatomy 0.000 description 1
• 208000029444 double vision Diseases 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 230000002996 emotional effect Effects 0.000 description 1
• 210000003372 endocrine gland Anatomy 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 239000003256 environmental substance Substances 0.000 description 1
• 230000001073 episodic memory Effects 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
• 235000019325 ethyl cellulose Nutrition 0.000 description 1
• 229920001249 ethyl cellulose Polymers 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 230000008921 facial expression Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 239000003269 fluorescent indicator Substances 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 239000012737 fresh medium Substances 0.000 description 1
• 201000006321 fundus dystrophy Diseases 0.000 description 1
• 238000003304 gavage Methods 0.000 description 1
• 229960002518 gentamicin Drugs 0.000 description 1
• 229940125384 geroprotector Drugs 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000026781 habituation Effects 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 230000005802 health problem Effects 0.000 description 1
• VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
• 230000000971 hippocampal effect Effects 0.000 description 1
• 239000003386 histamine H2 receptor agonist Substances 0.000 description 1
• 239000003453 histamine agonist Substances 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 235000012907 honey Nutrition 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
• 238000003365 immunocytochemistry Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000000099 in vitro assay Methods 0.000 description 1
• 238000005462 in vivo assay Methods 0.000 description 1
• 238000011065 in-situ storage Methods 0.000 description 1
• 239000005414 inactive ingredient Substances 0.000 description 1
• 150000002475 indoles Chemical class 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 230000010365 information processing Effects 0.000 description 1
• 238000002329 infrared spectrum Methods 0.000 description 1
• 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
• 230000002452 interceptive effect Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
• PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229960001317 isoprenaline Drugs 0.000 description 1
• 230000008449 language Effects 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000003715 limbic system Anatomy 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 238000002595 magnetic resonance imaging Methods 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 230000006984 memory degeneration Effects 0.000 description 1
• 208000023060 memory loss Diseases 0.000 description 1
• 210000002418 meninge Anatomy 0.000 description 1
• 230000003340 mental effect Effects 0.000 description 1
• 230000003924 mental process Effects 0.000 description 1
• 210000001259 mesencephalon Anatomy 0.000 description 1
• 229950008693 mesulergine Drugs 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 description 1
• 229960004650 metergoline Drugs 0.000 description 1
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 230000007625 mitochondrial abnormality Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 239000003068 molecular probe Substances 0.000 description 1
• 201000002003 mononeuritis multiplex Diseases 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 230000003387 muscular Effects 0.000 description 1
• 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
• 210000003007 myelin sheath Anatomy 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000001577 neostriatum Anatomy 0.000 description 1
• 210000005157 neural retina Anatomy 0.000 description 1
• 208000004296 neuralgia Diseases 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 238000002610 neuroimaging Methods 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 238000010984 neurological examination Methods 0.000 description 1
• 208000018360 neuromuscular disease Diseases 0.000 description 1
• 208000021722 neuropathic pain Diseases 0.000 description 1
• 230000007171 neuropathology Effects 0.000 description 1
• 239000004090 neuroprotective agent Substances 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 150000002825 nitriles Chemical class 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 201000001909 oculomotor nerve paralysis Diseases 0.000 description 1
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
• 238000001543 one-way ANOVA Methods 0.000 description 1
• 208000020911 optic nerve disease Diseases 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 150000002924 oxiranes Chemical class 0.000 description 1
• 238000012856 packing Methods 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 102000045222 parkin Human genes 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000001717 pathogenic effect Effects 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 210000000578 peripheral nerve Anatomy 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 229950010883 phencyclidine Drugs 0.000 description 1
• 239000008363 phosphate buffer Substances 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 229920000728 polyester Polymers 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 229920001155 polypropylene Polymers 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 208000028173 post-traumatic stress disease Diseases 0.000 description 1
• 229910000027 potassium carbonate Inorganic materials 0.000 description 1
• 229910000160 potassium phosphate Inorganic materials 0.000 description 1
• 235000011009 potassium phosphates Nutrition 0.000 description 1
• 229940069328 povidone Drugs 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000035935 pregnancy Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000002243 primary neuron Anatomy 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 201000002241 progressive bulbar palsy Diseases 0.000 description 1
• 230000001737 promoting effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• 238000000159 protein binding assay Methods 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 239000008213 purified water Substances 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
• 238000010992 reflux Methods 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 230000004043 responsiveness Effects 0.000 description 1
• 239000011369 resultant mixture Substances 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
• 230000000698 schizophrenic effect Effects 0.000 description 1
• 210000004116 schwann cell Anatomy 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 230000036280 sedation Effects 0.000 description 1
• 210000001044 sensory neuron Anatomy 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 108010006590 serotonin 5 receptor Proteins 0.000 description 1
• 239000003751 serotonin 6 antagonist Substances 0.000 description 1
• 229940121356 serotonin receptor antagonist Drugs 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 210000002027 skeletal muscle Anatomy 0.000 description 1
• 208000026473 slurred speech Diseases 0.000 description 1
• 230000011273 social behavior Effects 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 208000002320 spinal muscular atrophy Diseases 0.000 description 1
• 210000000273 spinal nerve root Anatomy 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 229940032147 starch Drugs 0.000 description 1
• 239000008107 starch Substances 0.000 description 1
• 235000019698 starch Nutrition 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000012258 stirred mixture Substances 0.000 description 1
• 238000003860 storage Methods 0.000 description 1
• 210000001913 submandibular gland Anatomy 0.000 description 1
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 230000002889 sympathetic effect Effects 0.000 description 1
• 230000007470 synaptic degeneration Effects 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• 239000003826 tablet Substances 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 229950011533 tiotidine Drugs 0.000 description 1
• 230000000451 tissue damage Effects 0.000 description 1
• 231100000827 tissue damage Toxicity 0.000 description 1
• 238000003325 tomography Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000419 toxicity Toxicity 0.000 description 1
• 230000001988 toxicity Effects 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000027 toxicology Toxicity 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
• 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
• GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 238000002562 urinalysis Methods 0.000 description 1
• 239000002435 venom Substances 0.000 description 1
• 231100000611 venom Toxicity 0.000 description 1
• 210000001048 venom Anatomy 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 210000001835 viscera Anatomy 0.000 description 1
• 201000007790 vitelliform macular dystrophy Diseases 0.000 description 1
• 208000020938 vitelliform macular dystrophy 2 Diseases 0.000 description 1
• 230000001755 vocal effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1
• UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
• AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical class N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 1